Published in Hepatitis Weekly, November 27th, 2006
The aim of the study was to determine the anti-viral effect, pharmacokinetic profile and safety of an oral therapy with Debio-025. The data, presented at the American Association for the Study of Liver Diseases (AASLD) conference, confirm the anti-viral effect of Debio-025 in HIV/HCV co-infected subjects.
The 15 day double-blind, placebo-controlled study, with twice daily...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.